Compare DNLI & FA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNLI | FA |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.4B |
| IPO Year | 2017 | 2021 |
| Metric | DNLI | FA |
|---|---|---|
| Price | $18.95 | $21.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 10 |
| Target Price | ★ $35.50 | $26.00 |
| AVG Volume (30 Days) | ★ 1.6M | 1.4M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.97 |
| EPS | N/A | ★ 0.11 |
| Revenue | N/A | ★ $1,574,389,000.00 |
| Revenue This Year | N/A | $8.35 |
| Revenue Next Year | $157.92 | $6.69 |
| P/E Ratio | ★ N/A | $190.50 |
| Revenue Growth | N/A | ★ 83.02 |
| 52 Week Low | $13.75 | $8.82 |
| 52 Week High | $27.30 | $25.15 |
| Indicator | DNLI | FA |
|---|---|---|
| Relative Strength Index (RSI) | 44.54 | 64.72 |
| Support Level | $17.75 | $19.47 |
| Resistance Level | $19.35 | $22.58 |
| Average True Range (ATR) | 0.77 | 0.81 |
| MACD | 0.21 | 0.26 |
| Stochastic Oscillator | 61.22 | 97.64 |
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
First Advantage Corp is a provider of software and data in the Human Resources technology industry. The company provides end-to-end identity solutions, criminal background screening, credential verifications, drug and health screening, and continuous risk monitoring. It combines AI-powered proprietary technology platforms with proprietary data, primary source data, and third-party data. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. The company generates maximum revenue from the Sterling segment, which provides similar services as compared to First Advantage's Americas and International segments on a global basis. Geographically, the company generates the majority of its revenue from the United States.